314
Participants
Start Date
December 12, 2019
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
MMH-407
MMH-407: For oral use.
Placebo
Placebo: For oral use.
Central Clinical Hospital of the Russian Academy of Sciences, Moscow
Tver State Medical University, Department of Hospital Therapy, Tver'
Vvedensky City Clinical Hospital, Saint Petersburg
City Polyclinic # 25 of the Nevsky District, Saint Petersburg
"Medical Center Reavita Med SPb", Saint Petersburg
"Llc Medical Clinic", Saint Petersburg
City Polyclinic # 43, Saint Petersburg
Belgorod State National Research University, Hospital Therapy Department, Belgorod
Kuban State Medical University, Infectious Diseases and Phthisiopulmonology Department, Krasnodar
Scientific Medical Center for General Therapy and Pharmacology, Stavropol
Volgograd State Medical University, Volgograd
Kazan State Medical University, Internal Medicine Department, Kazan'
City Clinical Hospital # 9 of the Ministry of Health of the Udmurt Republic, Izhevsk
Samara City Hospital # 4, Samara
Bashkir State Medical University, Internal Medicine Department, Ufa
Road Clinical Hospital at Chelyabinsk station of JSC Russian Railways, Chelyabinsk
City Clinical Hospital # 10 of the Kanavinsky District of Nizhny Novgorod, Nizhny Novgorod
Road Clinical Hospital at the station Nizhny Novgorod of JSC Russian Railways, Nizhny Novgorod
Altai State Medical University, Department of Faculty Therapy with a course of immunology and allergology, Barnaul
City Hospital # 5, Barnaul
Lead Sponsor
Materia Medica Holding
INDUSTRY